Investors highlight hot therapy areas in Asia Pacific

April 30, 2024

Antibody-drug conjugates are the hot spot for deals in Asia, but investors questioned whether oncology is really the place to be, during the Asia Bio Partnering Forum in Singapore April 24 to 25.

BioWorld Asia Conferences Deals and M&A Cancer Infection Antibody-drug conjugate Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for Sept. 25, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Sept. 24, 2025.

3D molecular view of liquid-liquid phase separation

Condensates and innate immunity in Clarivate’s Citation Laureates

BioWorld Science

Clarivate plc has unveiled the 2025 Citation Laureates. Widely considered a predictor of the Nobel Prizes, this recognition has highlighted the discovery of...

Human Cell Atlas discovers new targets in skin fibroblast subtypes

BioWorld Science

The Human Cell Atlas project has delivered a fresh tranche of data mapping fibroblasts in healthy and diseased skin and pointing to drug targets with potential in...

Illustration of antibodies attacking nerve cells

Aera Therapeutics selects AERA-109 for autoimmune diseases

BioWorld Science

Aera Therapeutics Inc. has nominated AERA-109, a targeted in vivo CAR T therapy designed to treat multiple B cell-mediated autoimmune diseases, as the company’s...